Baricitinib Clinical Trials
22 recruitingDrug
Phase 311Phase 29Phase 12Not Applicable1
Showing 1–20 of 22 trials
Recruiting
Phase 2
Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement
Kohlmeier-Degos DiseaseMalignant Atrophic PapulosisDegos Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)12 enrolled1 locationNCT06923072
Recruiting
Phase 3
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Long COVID
Wes Ely550 enrolled16 locationsNCT06631287
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled131 locationsNCT07222332
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled107 locationsNCT07222137
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company58 enrolled55 locationsNCT04088396
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
AlopeciaSkin DiseasesAreata Alopecia+3 more
Eli Lilly and Company595 enrolled127 locationsNCT05723198
Recruiting
Phase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled82 locationsNCT03773965
Recruiting
Phase 2
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Inflammatory Hepatocellular Adenoma
Assistance Publique - Hôpitaux de Paris25 enrolled1 locationNCT06490757
Recruiting
Phase 2
JAK Signaling in Depression
Major Depressive Disorder
Emory University100 enrolled1 locationNCT07003997
Recruiting
Phase 3
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Rheumatoid Arthritis
University of Nebraska400 enrolled1 locationNCT03414502
Recruiting
Phase 3
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Dermatomyositis
Assistance Publique - Hôpitaux de Paris62 enrolled1 locationNCT04972760
Recruiting
Molecular Signatures in Inflammatory Skin Disease
Atopic DermatitisPsoriasis
Prof. Dr. Stephan Weidinger300 enrolled1 locationNCT03358693
Recruiting
Phase 2
Inflammation and Depression in People With HIV
DepressionAnhedoniaHIV
Emory University60 enrolled2 locationsNCT05849038
Recruiting
Phase 2
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Chronic Kidney Diseases
Duke University75 enrolled1 locationNCT05237388
Recruiting
Phase 2
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
Behcet Syndrome, Intestinal Type
Peking Union Medical College Hospital56 enrolled2 locationsNCT06849908
Recruiting
Phase 2Phase 3
Vitiligo, New Treatment and Serum s100B
Vitiligo, Generalized
South Valley University50 enrolled1 locationNCT06768840
Recruiting
Phase 1Phase 2
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NMO Spectrum Disorder
Tianjin Medical University General Hospital12 enrolled1 locationNCT05792462
Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Alopecia AreataJanus Kinase Inhibitors
Second Affiliated Hospital, School of Medicine, Zhejiang University150 enrolled1 locationNCT06573593
Recruiting
Phase 1Phase 2
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
Pulmonary Injury After Intracerebral Hemorrhage
Tianjin Medical University General Hospital100 enrolled1 locationNCT06548802
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707